Jagsonpal Pharma

32
Sell
  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE048B01035
  • NSEID: JAGSNPHARM
  • BSEID: 507789
INR
205.20
-4.1 (-1.96%)
BSENSE

May 25

BSE+NSE Vol: 1.51 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 28.76% vs -11.83% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 121.40% vs -32.46% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 17.69% vs 97.09% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is 146.45% vs -15.94% in Mar 2024

Compare Profit and Loss Results of Jagsonpal Pharma
Markets Mojo
Figures in Cr
standalone - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
268.00
623.00
-355.00
-56.98%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
268.00
623.00
-355.00
-56.98%
Expenditure (Ex Depriciation)
Stock Adjustments
-2.00
8.00
-10.00
-125.00%
Raw Materials Consumed
98.00
282.00
-184.00
-65.25%
Power & Fuel Cost
0.00
11.00
-11.00
-100.00%
Employee Cost
70.00
112.00
-42.00
-37.50%
Operating Expenses
0.00
27.00
-27.00
-100.00%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
24.00
28.00
-4.00
-14.29%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
0.00
3.00
-3.00
-100.00%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
217.00
521.00
-304.00
-58.35%
Operating Profit (PBDIT) excl Other Income
51.00
101.00
-50.00
-49.50%
Other Income
8.00
22.00
-14.00
-63.64%
Operating Profit (PBDIT)
59.00
123.00
-64.00
-52.03%
Interest
0.00
1.00
-1.00
-100.00%
Profit before Depriciation and Tax
58.00
122.00
-64.00
-52.46%
Depreciation
8.00
12.00
-4.00
-33.33%
Profit Before Taxation & Exceptional Items
50.00
109.00
-59.00
-54.13%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
69.00
109.00
-40.00
-36.70%
Provision for Tax
14.00
26.00
-12.00
-46.15%
Profit After Tax
55.00
82.00
-27.00
-32.93%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
104.00
507.00
-403.00
-79.49%
Profit Available for appropriations
159.00
589.00
-430.00
-73.01%
Appropriations
159.00
589.00
-430.00
-73.01%
Equity Dividend (%)
125%
18%
107.00
Earnings Per Share
8.26
41.11
-32.85
-79.91%
Profit And Loss - Net Sales
Net Sales 268.72 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 28.76% vs -11.83% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 51.07 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 121.40% vs -32.46% in Mar 2024

Profit And Loss - Interest
Interest 0.96 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 17.69% vs 97.09% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 55.36 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 146.45% vs -15.94% in Mar 2024